CL2024002555A1 - Compuestos de cromanol para el tratamiento o profilaxis de trastornos asociados al envejecimiento. - Google Patents

Compuestos de cromanol para el tratamiento o profilaxis de trastornos asociados al envejecimiento.

Info

Publication number
CL2024002555A1
CL2024002555A1 CL2024002555A CL2024002555A CL2024002555A1 CL 2024002555 A1 CL2024002555 A1 CL 2024002555A1 CL 2024002555 A CL2024002555 A CL 2024002555A CL 2024002555 A CL2024002555 A CL 2024002555A CL 2024002555 A1 CL2024002555 A1 CL 2024002555A1
Authority
CL
Chile
Prior art keywords
aging
prophylaxis
treatment
chromanol
sul
Prior art date
Application number
CL2024002555A
Other languages
English (en)
Spanish (es)
Inventor
Henk Henning Robert
Krenning Guido
Cornelis Van Der Graaf Adrianus
Henri Swart Daniël
Original Assignee
Sulfateq Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sulfateq Bv filed Critical Sulfateq Bv
Publication of CL2024002555A1 publication Critical patent/CL2024002555A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2024002555A 2022-02-28 2024-08-27 Compuestos de cromanol para el tratamiento o profilaxis de trastornos asociados al envejecimiento. CL2024002555A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2031091A NL2031091B1 (en) 2022-02-28 2022-02-28 Chromanol compounds for treatment or prophylaxis of ageing and ageing-associated disorders

Publications (1)

Publication Number Publication Date
CL2024002555A1 true CL2024002555A1 (es) 2025-01-10

Family

ID=83271289

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002555A CL2024002555A1 (es) 2022-02-28 2024-08-27 Compuestos de cromanol para el tratamiento o profilaxis de trastornos asociados al envejecimiento.

Country Status (10)

Country Link
US (1) US20250177384A1 (https=)
EP (1) EP4486317A1 (https=)
JP (1) JP2025506844A (https=)
CN (1) CN118742301A (https=)
AU (1) AU2023225518A1 (https=)
CA (1) CA3252944A1 (https=)
CL (1) CL2024002555A1 (https=)
NL (1) NL2031091B1 (https=)
WO (1) WO2023163596A1 (https=)
ZA (1) ZA202406418B (https=)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105806A1 (en) 2005-04-07 2006-10-12 Miso Sabovic Delaying the ageing process and disorders caused by ageing
EP2680838A1 (en) 2011-02-28 2014-01-08 Farmicom Pharmaceutical Company D.O.O. TREATMENT OF ARTERIAL AGEING BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR
KR102137450B1 (ko) 2012-07-12 2020-07-27 콘드리온 아이피 비.브이. 미토콘드리아 질환을 치료하기 위한 크로마닐 유도체
NL2010010C2 (en) 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
WO2015148522A1 (en) 2014-03-24 2015-10-01 Seals Douglas R Methods for treatment of vascular endothelial dysfunction using nicotinamide mononucleotide
NL2013012B1 (en) * 2014-06-17 2016-07-05 Sulfateq Bv Compounds for the treatment of chronic obstructive airway diseases.
US10815211B2 (en) 2015-10-08 2020-10-27 Khondrion Ip B.V. Compounds for treating mitochondrial disease
ES2959243T3 (es) * 2017-04-05 2024-02-22 Khondrion Ip B V Nuevo tratamiento de enfermedades mitocondriales
EP3672593B1 (en) * 2017-08-25 2024-12-18 Sulfateq B.V. Medicaments for the treatment of vasoconstriction related diseases or disorders
WO2019038360A1 (en) * 2017-08-25 2019-02-28 Sulfateq B.V. 6-CHROMANOL DERIVATIVES FOR USE AS A MEDICINAL PRODUCT
NL2024431B1 (en) * 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease
NL2026511B1 (en) * 2020-09-21 2022-05-24 Sulfateq Bv Compounds for treatment of heart failure

Also Published As

Publication number Publication date
US20250177384A1 (en) 2025-06-05
CN118742301A (zh) 2024-10-01
AU2023225518A1 (en) 2024-09-12
EP4486317A1 (en) 2025-01-08
NL2031091B1 (en) 2023-09-07
JP2025506844A (ja) 2025-03-13
WO2023163596A1 (en) 2023-08-31
ZA202406418B (en) 2025-11-26
CA3252944A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
CL2023003041A1 (es) Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica
DOP2016000017A (es) Nuevos compuestos tricíclicos
MX378515B (es) Aminotriazolopiridinas como inhibidores de cinasa.
SV2009003411A (es) Compuestos de amino-heterociclico
CO2022011194A2 (es) Compuestos de sulfonimidamida como moduladores de nlrp3
DOP2013000055A (es) Nuevos compuestos tricíclicos
UY39303A (es) Inhibidores de mutación her2
GT200600166A (es) Derivados de cromano y cromeno y usos de los mismos
CL2020001564A1 (es) Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresina.
AR079467A1 (es) Derivados heterociclicos nitrogenados de etinilo, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos para tratar y/o prevenir enfermedades cognitivas o esquizofrenia.
JOP20220140A1 (ar) مركبات لعلاج مرض الزهايمر
CL2023003774A1 (es) Inhibidores de mutación de her2
CO2023004926A2 (es) Compuestos de triazolopiridinilo como inhibidores de quinasas
AR127470A1 (es) Inhibidores de lrrk2
CL2024004050A1 (es) Compuestos tricíclicos y usos de los mismos.
CO2024007424A2 (es) Derivados heterocíclicos bicíclicos microbiocidas
CL2023000800A1 (es) Compuestos de cromanol para el tratamiento de la insuficiencia cardíaca
AR133953A1 (es) Inhibidores del factor b del complemento y usos de los mismos
UY40495A (es) 1,3,5-triazinas 2,4,6-trisustituidas como moduladores de cx3cr1
MX2018004868A (es) Derivados de la pirrolidina.
CO2025011065A2 (es) Derivados tricíclicos de azepinona como inhibidores del sistema xc
CL2024002555A1 (es) Compuestos de cromanol para el tratamiento o profilaxis de trastornos asociados al envejecimiento.
MX2022000099A (es) Compuestos para el tratamiento del cancer.
MX2022007176A (es) 4-((2-oxopyri din-1 (2h)-yl)metil)benzamidas para el tratamiento de la deficiencia de alfa1-antitripsina.
CO2024004974A2 (es) Derivados de piridinilo como activadores del canal de sodio